Immunovant, Inc. today announced significant leadership changes and an expanded development strategy for its lead asset, IMVT-1402, marking a new phase of growth with increased alignment with Roivant Sciences. Eric Venker, M.D., Roivant’s President and an Immunovant Director, has been appointed as Immunovant’s new Chief Executive Officer, succeeding Pete Salzmann, M.D., who retired. Tiago Girao, formerly Telavant CFO, has taken over as Immunovant’s Chief Financial Officer from Renee Barnett.
These leadership transitions are part of a broader strategic realignment, as development activities for batoclimab begin to conclude and focus intensifies on IMVT-1402. The company also announced the expansion of IMVT-1402’s development into two new indications: Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE). The Investigational New Drug (IND) application for CLE is now active, and a proof-of-concept trial for IMVT-1402 in CLE has been initiated.
The board of directors also saw changes, with George Migausky stepping down and Robert Susman and Jacob Bauer joining the board, effective April 18, 2025. This strategic pivot and pipeline expansion aim to maximize the potential of IMVT-1402 across a wider range of autoimmune diseases, with the new leadership team tasked with driving clinical execution.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.